how to recover anti cancer

Sutent 12.5mg Sutent 12.5mg is an antineoplastic drug which prevents the growth and spread of cancer cells in the body. Sutent 12.5mg belongs to targeted therapy and is a receptor protein-tyrosine kinase inhibitor. It prohibits the actions of vascular endothelial growth factor (VEGF) and is an angiogenesis inhibitor. Sutent 12.5mg capsule is a prescription drugs which is used under the guidance of medical practioners INDICATION Sutent 12.5mg capsule is used for the treatment in patients having Gastrointestinal stromal tumor Sutent 12.5mg is used for the treatment in patients having Advanced pancreatic neuroendocrine tumor Sutent 12.5mg capsule  is used for the treatment in patients having Advanced renal cell cancer sutent 12.5mg,sutent 12.5mg capsule DOSAGE The recommended dosage for following condition as follows : Dose after disease progression on or intolerance to imatinib mesylate The usual dose for patients with Gastrointestinal Stromal Tumor is 50

Suninat 50mg Suninat 50mg is an antineoplastic drug which prevents the growth and spread of cancer cells in the body. Suninat 50mg belongs to targeted therapy and is a receptor protein-tyrosine kinase inhibitor. It prohibits the actions of vascular endothelial growth factor (VEGF) and is an angiogenesis inhibitor. Suninat 50mg is a prescription drugs which is used under the guidance of medical practioners INDICATION Suninat 50mg tablet is used for the treatment in patients having Gastrointestinal stromal tumor Suninat 50mg tablet is used for the treatment in patients having Advanced pancreatic neuroendocrine tumor Suninat 50mg is used for the treatment in patients having Advanced renal cell cancer suninat 50mg,suninat 50mg capsule DOSAGE The recommended dosage for following condition as follows : Dose after disease progression on or intolerance to imatinib mesylate The usual dose for patients with Gastrointestinal Stromal Tumor is 50 mg PO qDay for 4 weeks, followed

Herduo 250mg Herduo 250mg tablets are classified as an anti-cancer agent, which is orally active drug used for treating breast cancer. Chemically classified as quinazoline with strong anti-cancer effect and the tablet Herduo is a synthetic oral tablet. Normally targeted therapy or tyrosine kinase inhibitor drugs can increase the plasma aminotransferase levels which may lead to liver injury. Herduo 250mg tablets are classified as; 1.Tyrosine kinase prohibition 2.Stop the HER2/neu& epidermal growth factor receptor activity 3.Targeted therapy 4.Signal transduction prohibition. INDICATION Primarily Herduo 250mg tablet indicated for advanced breast cancer. Herduo 250mg is indicated for the combination with Capecitabine tablets are normally indicated for the treatment of metastatic breast cancer patients in whose cancer cells expressed with EGFR 2 (HER2) and already patients may get an anthracycline, taxane & Trastuzumab. herduo 250mg,herduo 250mg tab

Hertab 250mg Hertab 250mg tablets are classified as an anti-cancer agent, which is orally active drug used for treating breast cancer. Chemically classified as quinazoline with strong anti-cancer effect and the tablet Hertab 250mg is a synthetic oral tablet. Normally targeted therapy or tyrosine kinase inhibitor drugs can increase the plasma amino transferase levels which may leads to liver injury. Hertab tablets are classified as; 1.Tyrosine kinase prohibitor 2.Stop the HER2/neu & epidermal growth factor receptor activity 3.Targeted therapy 4.Signal transduction prohibitor INDICATION Primarily Hertab 250mg indicated for advanced breast cancer. Hertab is indicated for the combination with Capecitabine tablets are normally indicated for the treatment of metastatic breast cancer patients in whose cancer cells expressed with EGFR 2 (HER2) and already patients may get an anthracycline, taxane & Trastuzumab. hertab 250mg, hertab 250mg tablet DOSAGE In HER2 positive

Lapahope 250mg Lapahope 150mg tablets are classified as an anti-cancer agent, which is an orally active drug used for treating breast cancer. Chemically classified as quinazoline with strong anti-cancer effect and the tablet Lapahope 150mg tablet is a synthetic oral tablet. Normally targeted therapy or tyrosine kinase inhibitor drugs can increase the plasma amino transferase levels which may lead to liver injury. Lapahope 150mg tablets are classified as; 1.Tyrosine kinase prohibition 2. Stop the HER2/neu & epidermal growth factor receptor activity 3.Targeted therapy 4.Signal transduction prohibition. INDICATION Primarily Lapahope 150mg indicated for advanced breast cancer. Lapahope 150mg is indicated for the combination with Capecitabine tablets are normally indicated for the treatment of metastatic breast cancer patients in whose cancer cells expressed with EGFR 2 (HER2) and already patients may get an anthracycline, taxane & Trastuzumab. lapaho

Erlocip 150mg Erlocip 150mg tablets consist of active ingredients known as Erlotinib (Generic Tarceva), that is considered as quinazoline derivative and anti-cancer agents that responses as a protein kinase prohibition for EGFR related to tyrosine kinase. Erlocip is majorly used in the treatment of non-small cell lung cancer and pancreatic carcinoma and also involved to treat various cancers. Erlocip has especially aimed at the epidermal growth factor receptor tyrosine kinase. USES OF Erlocip Nonsmall cell lung cancer: Erlocip 150mg is indicated as continuance therapy, in patients with long-lasting or metastasis non-small cell lung carcinoma, whose disease has not to get advance after four cycles with platinum-based first-line therapy. Erlocip is used in this condition only after the failure of one prior chemotherapy regimen. No clinical advantages occur while using Erlocip with platinum-based compounds like Carboplatin, gemcitabine or cisplatin. Pancreatic cancer: Erlocip

Erlonat   150mg Erlonat 150mg tablets consist of active ingredients known as Erlotinib (Generic Tarceva), that is considered as quinazoline derivative and anti-cancer agents that responses as a protein kinase prohibitors for EGFR related to tyrosine kinase. Erlonat 150mg tablet is majorly used in the treatment of non-small cell lung cancer and pancreatic carcinoma and also involved to treat various cancers. Erlonat is especially aimed at the epidermal growth factor receptor tyrosine kinase. USES OF Erlonat Non small cell lung cancer: Erlonat 150mg tablet is indicated as continuance therapy, in patients with long lasting or metastasis non small cell lung carcinoma, whose disease has not get advance after four cycles with platinum based first line therapy. Erlonatis used in this condition only after the failure of one prior chemotherapy regimen. No clinical advantages occur while using Erlonat with platinum based compounds like Carboplatin, gemcitabine or cisplatin. Pancrea

Tykerb 250mg Tykerb 250mg tablets are classified as anti-cancer agent, which is orally active drug used for treating breast cancer Chemically classified as quinazoline with strong anti-cancer effect and the tablet Tykerb  250mg is a synthetic oral tablet Normally targeted therapy or tyrosine kinase inhibitor drugs are capable of increasing the plasma amino transferase levels which may lead to liver injury, the main ingredient which is used as lapatinib. Tykerbtablets are classified as; 1. Tyrosine kinase prohibitor 2. Stop the HER2/neu & epidermal growth factor receptor activity 3. Targeted therapy 4. Signal transduction prohibitor DOSAGE REGIMENS OF Tykerb  In HER2 positive advanced breast cancer: The usual dose of Tykerb is 1250mg should be given orally as a single dose on day 1 to 21 repeatedly concomitant with Capecitabine 2000mg/m2/day (administer 2 doses relatively 12 hours apart orally ) on day 1 to 14 in a continuous 21-day cycle. Sum of 5 tablets of Tykerb s